Avadel Stock Rises After Acquisition Offer By Alkermes
Synopsis
- Alkermes will buy Avadel for up to $20 per share.
- The consideration of $20 values Avadel at about $2.1 billion.
- The deal is expected to close in the first quarter of 2026.
Alkermes plc (ALKS) and Avadel Pharmaceuticals plc (AVDL) on Wednesday said that the companies have entered into a definitive agreement under which Alkermes will acquire Avadel for up to $20 per share.
The consideration of $20 values Avadel at about $2.1 billion and represents a premium of 12% from the stock’s last closing price on Tuesday.
When Will The Deal Close?
The deal has been approved by the board of directors of both companies and is expected to close in the first quarter (Q1) of 2026. The deal is expected to be accretive upon closing, Alkermes said. The transaction includes Avadel’s Lumryz for the treatment of cataplexy or excessive daytime sleepiness in patients over 7 years of age with narcolepsy.
AVDL stock is up 4% in the pre-market session.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.